Prothena | PRTA - Cost Of Sales


Prothena reported $28.94M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
ALKERMES USD 120.7M 47.44M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Exelixis USD 20.66M 704K Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026